Home › Targets › BAFF
BAFF (3 companies · 11 programs)
Companies with an active program directed at BAFF.
- TRUTAKNA — IgA Nephropathy Approved
- atacicept — Primary Membranous Nephropathy Phase 2
- atacicept — Focal Segmental Glomerulosclerosis Phase 2
- atacicept — Minimal Change Disease Phase 2
- VT-109 Preclinical
- VT-109 Preclinical
- atacicept — Membranous Nephropathy Phase 2
- telitacicept — Generalized Myasthenia Gravis Phase 3
- telitacicept — Sjögren's Disease Phase 3
- tibulizumab — Hidradenitis Suppurativa Phase 2
- tibulizumab — Diffuse Cutaneous Systemic Sclerosis Phase 2
